| Working principleJudged by how the thing works | Arthur 2009Own terms: improvement; radically new | Improves something that works on the same base principle. | Radical: uses a new base principle for the same purpose. | A high-fidelity Cas9 that cuts the same way with fewer off-target edits is incremental. RNA-guided Cas9, replacing protein-guided zinc-finger and TALEN editing for the same purpose, is a new principle. | No new principle. The three advances it combines already exist. |
| FrameworkJudged by the community, usually in hindsight | Kuhn 1962, Dosi 1982Own pairs: normal science and revolution (Kuhn); trajectory and paradigm (Dosi) | Normal progress inside the accepted problems and standards. | Radical: changes what counts as a problem and as a good answer. | Mapping one more variant in a known pathway is normal progress. Treating peptic ulcer as a bacterial infection, not a result of stress and acid, changed the question. | The central hypothesis, if it held, would change what counts as a window of vulnerability. That is the bold part. Whether it is framework-changing is for others to judge, later. |
| ArchitectureJudged by whether the links between parts changed | Henderson and Clark 1990Own pair: incremental and radical, with modular and architectural between them | Changes a component and keeps the links between components. | Radical: new components and new links. A third kind keeps the components and changes the links. It can look minor and still hurt established firms. | CAR-T cells join antibody-derived binding domains to T-cell signalling domains: known parts, a new linkage. | Closest fit: known parts, put together in a new way. |
| MarketJudged by what happens in the market over years | Christensen 1997Own pair: sustaining and disruptive | Called "sustaining": serves current customers better. It can be technically radical. | Not a radical claim. Christensen's own term is disruptive: it starts with overlooked customers, with a simpler or cheaper offer, then moves up. | A first-in-class drug for the same patients and prescribers is sustaining, however new its mechanism. A simple point-of-care test that starts below laboratory accuracy and improves is the kind of case the disruption literature describes. | No market claim. There is no company. |
| CitationsJudged by an index over many papers, not by importance | Wu 2019, Park 2023Own pair: consolidating and disrupting | Consolidating: later papers cite it together with the work it builds on. | Disrupting: later papers cite it and leave out the work it builds on. | Park and colleagues report the decline across fields, including the life sciences. Wu and colleagues find that small teams disrupt and large teams develop. | Not a claim I can make about my own work. |
| Who judges, and whenJudged by who is asked, and how long they wait | Kuhn 1962, Dosi 1982Own pairs: normal and revolutionary (Kuhn); trajectory and paradigm (Dosi) | Judged inside the standards in force. Within a paradigm an agreed criterion of progress exists (Dosi). | The standards are part of what is in question, so a verdict needs the community and usually time (Kuhn). Even after the fact, comparing two directions can be ambiguous (Dosi). | The bacterial account of peptic ulcer was contested for years before it replaced the stress-and-acid account. | I do not judge my own work radical. Others decide, and later. |
| Can it be plannedJudged by what plans achieved, a debated point | Stanley and Lehman 2015, Vinsel and Russell 2020, Christensen 1997Own pair: modest and ambitious objectives (Stanley and Lehman) | A plan with modest objectives works: an objective only a stepping stone away is sensible to set and follow. | The sources disagree. Stanley and Lehman argue that fixed objectives mislead when the goal is ambitious. Vinsel and Russell say disruption cannot be worked toward or planned. Christensen advises planning to learn, on the assumption that forecasts are wrong. | Drakeman and colleagues (2021) use FDA priority review as their proxy for breakthrough drugs. For 1998 to 2016 they report biotech companies originated more of them than large pharma, and credit many parallel projects stopped quickly when they fail. The authors have a stake in the industry. Book. | No plan can promise a radical result. Each aim of the recorder programme has a test that can fail, and its criteria were fixed before any data were seen. |
| AI-enabled scienceJudged by what was actually tested: few results, mostly small | Boden 1998, Gao 2024, Ding and Li 2025Own pair: exploratory and transformational creativity (Boden) | Exploring a defined space faster. Boden found exploratory creativity the most successful kind in AI. | Changing the space itself (Boden's transformational creativity) is harder still for AI. Gao and colleagues describe agents that generate creative, de novo hypotheses as a level that has yet to be realized. | In one simulated lac-operon task, ChatGPT-4 produced fewer hypotheses than human subjects and never noticed an anomaly. The authors ran it twice, and the human data came from an earlier study. | I do not call a result radical because AI produced it. The rules for AI use in this lab are on the Resources page. |